Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.ncbi.nlm.nih.gov › pmc › articlesPotassium-competitive acid blockers - are they the next...

    13 de dic. de 2018 · Potassium-competitive acid blockers (P-CABs) are novel drugs that bind reversibly to K + ions and block the H +, K + ATPase enzyme, thus preventing acid production. P-CABs have a fast onset of action and have dose-dependent effects on acid production.

    • PMC Free Article

      What are potassium-competitive acid blockers? The first drug...

    • PubMed

      Vonoprazan (Takecab(®)) is an orally bioavailable...

  2. pubmed.ncbi.nlm.nih.gov › 36865588Potassium-Competitive Acid Blockers: Present and Potential ... -...

    Potassium-competitive acid blockers (PCABs) such as vonoprazan represent a novel class of acid suppressants that show tremendous promise to enhance care of acid peptic disorders. PCAB characteristics distinct from those of proton pump inhibitors-such as acid stability with dosing independent of food ….

  3. link.springer.com › article › 10Acid Suppressant Therapy: a Step Forward with...

    25 de ene. de 2021 · However, a major advance has been the development of the potassium-competitive acid blockers (P-CABs), which block the K + ,H + -ATPase potassium channel, are food independent, are reversible, have a rapid onset of action, and maintain a prolonged and consistent elevation of intragastric pH.

  4. www.tandfonline.com › doi › fullFull article: Potassium-competitive acid blockers: rethinking...

    6 de mar. de 2024 · Gastroenterology. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori. Carol M. Antequera. , Kimberly Orleck. , Rinu Jacob. , Amy Kenneally. & Wendy L. Wright. Received 18 Oct 2023, Accepted 13 Feb 2024, Published online: 06 Mar 2024. Cite this article.

  5. www.ncbi.nlm.nih.gov › pmc › articlesPotassium-competitive acid blockers, a new therapeutic class, and...

    15 de ago. de 2022 · The pKa is an important marker: the lower the pKa value, the stronger the acid. The pKa of these drugs varies between 5.6 ( SCH28080 ), 6.1 (linaprazan), and 9.3 (vonoprazan). Considering that vonoprazan has a high pKa (at 9.3), most of it is protonated easily and exerts its inhibitory action.

  6. onlinelibrary.wiley.com › doi › fullAlimentary Pharmacology & Therapeutics - Wiley Online Library

    16 de feb. de 2021 · Volume 53, Issue 7. April 2021. Pages 794-809. Summary Background Potassium-competitive acid blockers (P-CABs) are a novel group of acid-suppressing medicines for the management of acid-related disorders. Aims To review published clinical pharm...

  7. pubmed.ncbi.nlm.nih.gov › 29739175Potent Potassium-competitive Acid Blockers: A New Era for the ......

    30 de jul. de 2018 · Potassium-competitive acid blockers (P-CABs) were developed and have beneficial effects including rapid, long-lasting, and reversible inhibition of the gastric hydrogen potassium ATPase, the proton pump of the stomach. Vonoprazan was recently innovated as a novel, orally active P-CAB.